Robbins LLP Announces Class Action Against PepGen Inc. for Investors' Misconduct
On June 10, 2025, Robbins LLP, a prominent law firm specializing in shareholder rights, announced a significant class action lawsuit against PepGen Inc., a clinical-stage biotechnology company. This legal action has been prompted by allegations that PepGen misled investors regarding its lead drug candidate, PGN-EDO51, designed to treat Duchenne muscular dystrophy (DMD). Investors who acquired PepGen securities between March 7, 2024, and March 3, 2025, may potentially be part of this legal claim.
PepGen, which is known for developing innovative oligonucleotide therapeutics to tackle serious neuromuscular and neurological diseases, recently encountered serious scrutiny regarding its drug's efficacy and safety. According to the claims lodged, PepGen allegedly failed to provide accurate information regarding critical aspects of PGN-EDO51, namely its effectiveness and safety profile. There are troubling indications that the outcomes from the CONNECT2 study could endanger the approval process by the U.S. Food and Drug Administration (FDA).
The controversy came to a head when a press release, dated January 29, 2025, disclosed serious safety concerns relating to the CONNECT1 study. It indicated that one participant's dosage had to be paused due to a decrease in their estimated glomerular filtration rate, raising alarm bells about the drug's safety metrics. Additionally, the company faced increased scrutiny from Health Canada, demanding more information on the safety concerns before proceeding with dose escalations or enrolment of new participants at the current dose levels. Following this announcement, PepGen's stock saw a sharp decline, dropping 21.74% the day after the news broke, closing down to $1.44.
The situation escalated further on March 4, 2025, when PepGen announced the temporary suspension of the CONNECT2 study, indicating the company needed to assess the results of another ongoing study before proceeding. This prompted a further decrease in share price, down 18.86% to $2.28. With the company's public image and stock price heavily impacted by these revelations, investors are understandably concerned about the actions of PepGen's management team.
Robbins LLP is actively seeking individuals who invested in PepGen during the specified timeframe to join the class action as lead plaintiffs. Current shareholders are advised that they must file a motion by August 8, 2025, if they wish to take on this role. However, participation in this case is not a prerequisite for compensation; absent class members may still be eligible for any recovery related to the lawsuit.
The firm, well-recognized in shareholder rights advocacy since 2002, highlights that all legal representation offered will be on a contingency basis, meaning shareholders pay no upfront fees or expenses, allowing more individuals to seek justice without financial burden.
Robbins LLP aims to keep investors informed about the ongoing developments regarding PepGen and possible outcomes of the lawsuit. Anyone interested in updates about this class action or who desires further information can sign up for free alerts via the firm's Stock Watch service.
This unfolding legal matter shines a light on the importance of corporate transparency and accountability, especially in the biotech sector, where investors' trust hinges on the efficacy and safety of drug development efforts. As the class action progresses, the implications will undoubtedly extend beyond PepGen, marking a critical moment for all stakeholders in the field of biotechnology.
For additional insights into the legal actions against PepGen Inc. and the broader context of shareholder rights, keep an eye on further announcements from Robbins LLP.
PepGen, which is known for developing innovative oligonucleotide therapeutics to tackle serious neuromuscular and neurological diseases, recently encountered serious scrutiny regarding its drug's efficacy and safety. According to the claims lodged, PepGen allegedly failed to provide accurate information regarding critical aspects of PGN-EDO51, namely its effectiveness and safety profile. There are troubling indications that the outcomes from the CONNECT2 study could endanger the approval process by the U.S. Food and Drug Administration (FDA).
The controversy came to a head when a press release, dated January 29, 2025, disclosed serious safety concerns relating to the CONNECT1 study. It indicated that one participant's dosage had to be paused due to a decrease in their estimated glomerular filtration rate, raising alarm bells about the drug's safety metrics. Additionally, the company faced increased scrutiny from Health Canada, demanding more information on the safety concerns before proceeding with dose escalations or enrolment of new participants at the current dose levels. Following this announcement, PepGen's stock saw a sharp decline, dropping 21.74% the day after the news broke, closing down to $1.44.
The situation escalated further on March 4, 2025, when PepGen announced the temporary suspension of the CONNECT2 study, indicating the company needed to assess the results of another ongoing study before proceeding. This prompted a further decrease in share price, down 18.86% to $2.28. With the company's public image and stock price heavily impacted by these revelations, investors are understandably concerned about the actions of PepGen's management team.
Robbins LLP is actively seeking individuals who invested in PepGen during the specified timeframe to join the class action as lead plaintiffs. Current shareholders are advised that they must file a motion by August 8, 2025, if they wish to take on this role. However, participation in this case is not a prerequisite for compensation; absent class members may still be eligible for any recovery related to the lawsuit.
The firm, well-recognized in shareholder rights advocacy since 2002, highlights that all legal representation offered will be on a contingency basis, meaning shareholders pay no upfront fees or expenses, allowing more individuals to seek justice without financial burden.
Robbins LLP aims to keep investors informed about the ongoing developments regarding PepGen and possible outcomes of the lawsuit. Anyone interested in updates about this class action or who desires further information can sign up for free alerts via the firm's Stock Watch service.
This unfolding legal matter shines a light on the importance of corporate transparency and accountability, especially in the biotech sector, where investors' trust hinges on the efficacy and safety of drug development efforts. As the class action progresses, the implications will undoubtedly extend beyond PepGen, marking a critical moment for all stakeholders in the field of biotechnology.
For additional insights into the legal actions against PepGen Inc. and the broader context of shareholder rights, keep an eye on further announcements from Robbins LLP.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.